Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback

Equity Bottom-Up

214 Views, 15 Jan 2022 23:01

EXECUTIVE SUMMARY

Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.

detail (4-minute read)

WHAT’S TRENDING

Insights